ERBB2 and breast carcinoma: This study presents a systematic analysis of adverse events associated with Tucatinib, Lapatinib, and Neratinib in the treatment of HER-2 positive breast cancer, utilizing FAERS database data to elucidate the key safety characteristics and toxicity profiles of these drugs.